Sourbier Carole
Rockville, MD, USA.
Biologics. 2012;6:147-54. doi: 10.2147/BTT.S24155. Epub 2012 Jun 20.
With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients.
2012年美国估计有22000例新发病例，15500例相关死亡病例，卵巢癌是一种异质性且侵袭性的疾病。尽管大多数患者在手术后对化疗敏感，但复发性疾病几乎总是致命的，只有约30%受影响的女性能够治愈。由于对卵巢癌恶性肿瘤潜在分子机制有了更好的理解，分子靶向药物的新治疗选择已经出现。本综述讨论了分子靶向治疗背后的基本原理，并探讨新发现的分子靶点如何增强卵巢癌患者的个性化治疗。
